Middle East Pharmaceutical Company Ltd. (4016)
Tadawul
64.75
+1.30 (+2.05%)
Closed
Aug 27, 2026
Day's Range
63.2064.80
52 wk Range
53.8979.09
Financial Statements - 4016 - Middle East Pharmaceutical Company Ltd.
Revenue
460.48M▲ 16.9%
Net Income
97.00M▲ 21.5%Net Margin 21.1%
EBITDA
128.37M▲ 21.2%
Free Cash Flow
54.12M▲ 277.3%
Income Statement
| Period Ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Sales | 460.48M | 394M |
| Cost of Goods | 173.64M | 150.63M |
| Gross Profit | 286.83M | 243.36M |
 Operating Expense | - | - |
| Operating Income | 109.33M | 94.60M |
| Non-Operating Interest | - | - |
| Other Income Expense | - | - |
| Pre Tax Income | 103.73M | 86.34M |
| Income Tax | 6.73M | 6.50M |
| Net Income | 97M | 79.84M |
| EPS Basic | 2.771429 | 3.99 |
| EPS Diluted | 2.771429 | 3.99 |
| Basic Shares Outstanding | 35M | 20M |
| Diluted Shares Outstanding | 35M | 20M |
| Ebit | 108.41M | 87.36M |
| Ebitda | 128.37M | 105.96M |
| Net Income Continuous Operations | 103.73M | 79.84M |
| Minority Interests | - | - |
| Preferred Stock Dividends | 0 | 0 |
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
